Abundant preclinical and clinical data suggest that blocking the function of EGFR can enhance the efficacy of chemotherapy and radiotherapy and promote tumor regression in epithelial and squamous carcinomas [14]. The gene discussed is EGFR; the disease is squamous cell carcinoma.